Home2018-09-24T20:02:27+00:00

CHS 2017 Annual Report

The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.

LEARN MORE

Hemophilia Today

Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.

LEARN MORE

Call for applications

The Canadian Hemophilia Society (CHS) has put out its call for applications for its research programs for the 2019-2020 grant period. The deadline to submit applications for all the programs is November 15, 2018. The eligibility criteria and conditions for all our research programs have been revised and updated.

LEARN MORE

Retreat

LATE APPLICATIONS WELCOME, ON A FIRST COME FIRST SERVE BASIS, UNTIL ALL SPONSORSHIPS HAVE BEEN ATTRIBUTED:
The goal of this retreat is to address current needs of people ageing with a bleeding disorder and help address future needs. The CHS will offer about 30 sponsorships to Canadian men and women, aged 50 years and over, living with a bleeding disorder, and their caregiver/support person, to attend.

LEARN MORE

STRATEGIC PLAN  |  2016‐2020

LEARN MORE

Hemlibra (emicizumab) approved by Health Canada

Please CLICK HERE to read Roche’s press release announcing the approval of Hemlibra, a new therapy for patients with hemophilia A and inhibitors.

Q&A about RFPs

We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.

Learn more

Recombinant factor concentrate charts

Please check out our updated charts listing the recombinant factor concentrates and their description.

Click here for the rFVIII chart

Click here for the rFIX chart

REACH US AT

1-800-668-2686

chs@hemophilia.ca

WE’RE HERE TO HELP.

CONTACT US

FIND A TREATMENT CENTRE NEAR YOU

SEARCH